论文部分内容阅读
目的:观察孟鲁司特对婴幼儿毛细支气管炎疗效及喘息复发的影响。方法:将2008年10月～2009年4月在我院住院治疗的60例毛细支气管炎的患儿随机分为观察组和对照组各30例,两组患儿均采用相同的综合治疗方法,观察组在综合治疗的基础上加用孟鲁司特,每晚睡前口服,在症状发作1周内服用,持续4周后停药。治疗前后分别检测LTC4,ECP。结果:观察组症状、体症消失时间较对照组明显缩短(P<0.01),6个月内喘息复发率明显低于对照组(P<0.05)。观察组和对照组出院后随访1个月,血清LTC4,ECP均有下降,而观察组在服药4周后与对照组相比较,血清LTC4,ECP下降更加明显,差异有统计学意义,且LTC4下降有非常显著差异(P<0.01)。结论:口服孟鲁司特治疗婴幼儿毛细支气管炎,可以改善症状,缩短病程。连续服用4周,可降低喘息再发频率,改善预后。
Objective: To observe the effect of montelukast on infant bronchiolitis efficacy and recurrence of asthma. Methods: A total of 60 children with bronchiolitis treated in our hospital from October 2008 to April 2009 were randomly divided into observation group (30 cases) and control group (30 cases). The same treatment was used in both groups. The observation group combined with montelukast on the basis of comprehensive treatment, orally every night before going to bed, taking within 1 week of symptom onset, discontinued for 4 weeks. Before and after treatment were detected LTC4, ECP. Results: The disappearance time of symptom and symptom in observation group was significantly shorter than that in control group (P <0.01). The recurrence rate of wheezing in 6 months was significantly lower than that in control group (P <0.05). In the observation group and the control group, the levels of LTC4 and ECP decreased after one month’s follow-up after discharge. Compared with the control group, the levels of LTC4 and ECP in the observation group decreased more obviously after 4 weeks of treatment, and the difference was statistically significant There is a very significant difference (P <0.01). Conclusion: Oral montelukast treatment of infant bronchiolitis can improve symptoms and shorten the course of disease. Taking for 4 weeks continuously can reduce the recurrence frequency of wheezing and improve the prognosis.